<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD with OASIS Tables v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing-oasis-article1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Emerg Microbes Infect</journal-id><journal-id journal-id-type="iso-abbrev">Emerg Microbes Infect</journal-id><journal-id journal-id-type="publisher-id">TEMI</journal-id><journal-id journal-id-type="publisher-id">temi20</journal-id><journal-title-group><journal-title>Emerging Microbes &#x00026; Infections</journal-title></journal-title-group><issn pub-type="epub">2222-1751</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6334779</article-id><article-id pub-id-type="pmid">30866765</article-id><article-id pub-id-type="publisher-id">1561158</article-id><article-id pub-id-type="doi">10.1080/22221751.2018.1561158</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Mycobacterial genomics and structural bioinformatics: opportunities and challenges in drug discovery</article-title><alt-title alt-title-type="running-title">Emerging Microbes &#x00026; Infections</alt-title><alt-title alt-title-type="running-authors">V. P. Waman et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Waman</surname><given-names>Vaishali P.</given-names></name><xref ref-type="aff" rid="AF1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vedithi</surname><given-names>Sundeep Chaitanya</given-names></name><xref ref-type="aff" rid="AF1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>Sherine E.</given-names></name><xref ref-type="aff" rid="AF1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bannerman</surname><given-names>Bridget P.</given-names></name><xref ref-type="aff" rid="AF1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Munir</surname><given-names>Asma</given-names></name><xref ref-type="aff" rid="AF1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Skwark</surname><given-names>Marcin J.</given-names></name><xref ref-type="aff" rid="AF1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Malhotra</surname><given-names>Sony</given-names></name><xref ref-type="aff" rid="AF2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Blundell</surname><given-names>Tom L.</given-names></name><xref ref-type="aff" rid="AF1"><sup>a</sup></xref><xref ref-type="corresp" rid="cor1"><sup>CONTACT</sup></xref></contrib><aff id="AF1"><label>a</label><institution>Department of Biochemistry, University of Cambridge</institution>, Cambridge, <country>UK</country></aff><aff id="AF2"><label>b</label><institution>Institute of Structural and Molecular Biology, Department of Biological Sciences, Birkbeck College, University of London</institution>, London, <country>UK</country></aff></contrib-group><author-notes><corresp id="cor1"><label>CONTACT</label> Tom L. Blundell <email xlink:href="tlb20@cam.ac.uk">tlb20@cam.ac.uk</email><institution>Department of Biochemistry, University of Cambridge</institution>, <addr-line>Tennis Court Rd</addr-line>, CambridgeCB2 1GA, <country>UK</country></corresp></author-notes><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>16</day><month>1</month><year>2019</year></pub-date><volume>8</volume><issue>1</issue><fpage seq="13">109</fpage><lpage>118</lpage><history><date date-type="received"><day>15</day><month>10</month><year>2018</year></date><date date-type="rev-recd"><day>03</day><month>12</month><year>2018</year></date><date date-type="accepted"><day>09</day><month>12</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2019 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="temi-8-1561158.pdf"/><abstract><title>ABSTRACT</title><p>Of the more than 190 distinct species of <italic>Mycobacterium</italic> genus, many are economically and clinically important pathogens of humans or animals. Among those mycobacteria that infect humans, three species namely <italic>Mycobacterium tuberculosis</italic> (causative agent of tuberculosis), <italic>Mycobacterium leprae</italic> (causative agent of leprosy) and <italic>Mycobacterium abscessus</italic> (causative agent of chronic pulmonary infections) pose concern to global public health. Although antibiotics have been successfully developed to combat each of these, the emergence of drug-resistant strains is an increasing challenge for treatment and drug discovery. Here we describe the impact of the rapid expansion of genome sequencing and genome/pathway annotations that have greatly improved the progress of structure-guided drug discovery. We focus on the applications of comparative genomics, metabolomics, evolutionary bioinformatics and structural proteomics to identify potential drug targets. The opportunities and challenges for the design of drugs for <italic>M. tuberculosis</italic>, <italic>M. leprae</italic> and <italic>M. abscessus</italic> to combat resistance are discussed.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>Mycobacterium</kwd><kwd>comparative genomics</kwd><kwd>structure-guided drug discovery</kwd><kwd>drug resistance</kwd><kwd>mutation</kwd></kwd-group><funding-group><award-group><funding-source><named-content content-type="funder-name">The Botnar Foundation</named-content></funding-source><award-id>Project 6063</award-id></award-group><award-group><funding-source><named-content content-type="funder-name">The Cystic Fibrosis Trust</named-content><named-content content-type="funder-identifier">10.13039/501100000292</named-content></funding-source><award-id>Strategic Centre Award-201</award-id></award-group><award-group><funding-source><named-content content-type="funder-name">American Leprosy Mission</named-content></funding-source><award-id>G88726</award-id></award-group><award-group><funding-source><named-content content-type="funder-name">The Cambridge Commonwealth Trust</named-content><named-content content-type="funder-identifier">10.13039/501100003342</named-content></funding-source><award-id>Project 10380426</award-id></award-group><award-group><funding-source><named-content content-type="funder-name">the Pakistan HEC Cambridge Scholarship</named-content></funding-source></award-group><award-group><funding-source><named-content content-type="funder-name">Medical Research Council</named-content><named-content content-type="funder-identifier">10.13039/501100000265</named-content></funding-source></award-group><funding-statement>We thank following funding agencies for support of the Blundell group. SM: Medical Research Council, SCV: American Leprosy Mission [grant number G88726], MJS: The Botnar Foundation (Project 6063), SET: The Cystic Fibrosis Trust (Strategic Centre Award-201), AM; The Cambridge Commonwealth Trust (Project 10380426) and the Pakistan HEC Cambridge Scholarship.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="0"/><equation-count count="0"/><ref-count count="100"/><page-count count="10"/></counts></article-meta></front><body><sec id="S001"><title>Mycobacteria: the global disease burden</title><p>Mycobacteria belong to the genus <italic>Mycobacterium</italic>, which is the only genus representing the <italic>Mycobacteriaceae</italic> family (order: <italic>Actinomycetales</italic>; class: <italic>Actinobacteria</italic>). The genus was proposed in 1896, to include two species namely tubercle bacillus (now known as <italic>Mycobacterium tuberculosis</italic>) and leprosy bacillus (<italic>Mycobacterium leprae</italic>) [<xref rid="CIT0001" ref-type="bibr">1</xref>]. Currently, there are &#x0003e;190 distinct species of <italic>Mycobacterium</italic> genus, some of which are economically and clinically important pathogens of humans or animals [<xref rid="CIT0002" ref-type="bibr">2</xref>].</p><p>Among the human mycobacterial infections, those caused by <italic>M. tuberculosis</italic> (tuberculosis), <italic>M. leprae</italic> (leprosy) and <italic>Mycobacterium abscessus</italic> (chronic pulmonary infections) pose a public health concern. Mycobacterial infections affect &#x0223c;11&#x02013;14 million people each year globally and tuberculosis (TB) alone is responsible for &#x0223c;1.3 million deaths each year, of which 374,000 were people living with HIV/AIDS. In 2016, 10.4 million people living with HIV/AIDS, were diagnosed with TB [<xref rid="CIT0003" ref-type="bibr">3</xref>].</p><p>In case of <italic>M. leprae</italic> infections, the World Health Organization (WHO) reported &#x0223c;200,000 new cases of leprosy each year (<ext-link ext-link-type="uri" xlink:href="http://www.who.int/wer/2017/wer9235/en/">http://www.who.int/wer/2017/wer9235/en/</ext-link>). In 2016, 214,783 new cases of leprosy were reported globally. India reported the highest number (135,485) and Brazil 25,218 cases. Lack of effective early diagnostic tool(s), vaccines and limited understanding of the patterns of transmission contribute to the ongoing incidence.</p><p>In addition to TB and leprosy, Non-Tuberculous Mycobacteria (NTM), such as <italic>M. abscessus complex,</italic> are emerging worldwide as the cause of chronic pulmonary infections [<xref rid="CIT0004" ref-type="bibr">4</xref>,<xref rid="CIT0005" ref-type="bibr">5</xref>]. Incidence rates of pulmonary infections due to NTM, vary greatly with geographical regions. The global incidence remained 1.0&#x02013;1.8 in a population of 100,000, however, these rates are much higher in the US, Western Pacific and Canada [<xref rid="CIT0005" ref-type="bibr">5</xref>]. The prevalence of NTMs has increased from 1.3% [<xref rid="CIT0006" ref-type="bibr">6</xref>] to 32.7% in Colorado, in cystic fibrosis patients [<xref rid="CIT0007" ref-type="bibr">7</xref>].</p><sec id="S001-S2001"><title>The growing challenge of antimicrobial resistance</title><p>The past few decades have seen a &#x0201c;discovery void&#x0201d; pertaining to antibacterial drug development, where very few new molecules have been patented or approved for clinical use [<xref rid="CIT0008" ref-type="bibr">8</xref>]. This is particularly true for drug discovery against mycobacteria, where no new drugs that were specifically developed for this purpose reached the clinic after the early 1960s until recently [<xref rid="CIT0009" ref-type="bibr">9</xref>]. Importantly, the emergence of resistance towards first-line and second-line drugs poses additional challenges to the development of suitable drugs in each of <italic>M. tuberculosis</italic>, <italic>M. leprae</italic> and <italic>M. abscessus</italic>. The approval of drugs and causes of resistance have been systematically reviewed for <italic>M. tuberculosis</italic> [<xref rid="CIT0010" ref-type="bibr">10</xref>,<xref rid="CIT0011" ref-type="bibr">11</xref>], <italic>M. abscessus</italic> [<xref rid="CIT0012" ref-type="bibr">12</xref>] and <italic>M. leprae</italic> [<xref rid="CIT0013" ref-type="bibr">13</xref>]. Antibiotic resistance can arise due to physiological, intrinsic or acquired factors [<xref rid="CIT0010" ref-type="bibr">10</xref>,<xref rid="CIT0014" ref-type="bibr">14</xref>]. The intrinsic resistance is attributed to cell-wall permeability, drug efflux systems, drug targets with low affinity and enzymes that neutralize drugs in the cytoplasm. The acquired resistance is conferred by chromosomal mutations.</p><p>Although the TB mortality rate is falling at &#x0223c;3% per year globally, drug-resistant TB remains a continuing threat [<xref rid="CIT0003" ref-type="bibr">3</xref>]. The spread of drug-resistant strains of TB (mono-resistant, multidrug-resistant, extensively drug-resistant and totally drug-resistant) is alarmingly high and accounted for 490,000 cases of multidrug-resistant TB (MDR-TB) in 2016. Around 47% of the MDR-TB cases are reported in Southeast Asia [<xref rid="CIT0015" ref-type="bibr">15</xref>]. Increase in isoniazid-susceptible rifampin resistance was also noted in 2016, with 110,000 cases globally. The global burden of MDR-TB has recently increased by &#x0003e;20% annually [<xref rid="CIT0016" ref-type="bibr">16</xref>] and the treatment is successful in only 50% of the MDR-TB cases. With the ongoing transmission of the drug-resistant strains of <italic>M. tuberculosis</italic> in communities, it is increasingly important to research novel drug targets and identify potential leads that can be expanded to new drugs.</p><p>Drug resistance in leprosy is diagnosed by the mouse footpad method, which is time and labour-intensive. Alternatively, mutations can be detected in drug-resistance-determining regions of <italic>M. leprae</italic> drug targets such as dihydropteroate synthase (for the drug: dapsone), &#x003b2; subunit of RNA polymerase (rifampin) and subunit A of DNA gyrase (ofloxacin). As drug resistance has been suspected only in cases that self-report at the hospital as a result of reactivation or relapse in leprosy, the numbers are currently low; however, these may increase if a field-based surveillance system is implemented.</p><p><italic>M. abscessus</italic> is naturally resistant to many first-line antimicrobials, including all the current TB drugs. The acquired resistance to aminoglycosides is known to be due to mutations in genes such as <italic>rrs</italic> [<xref rid="CIT0012" ref-type="bibr">12</xref>]. Likewise, mutations in 23S rRNA and genes such as <italic>erm(41)</italic> and <italic>rrl</italic> are known to cause macrolide resistance in <italic>M. abscessus</italic> [<xref rid="CIT0017" ref-type="bibr">17</xref>].</p><p>Thus, emergence of antibiotic-resistant strains and rapid spread due to globalization poses a serious challenge to the global health [<xref rid="CIT0018" ref-type="bibr">18</xref>]. Genomics has served as an important milestone in bacterial drug discovery [<xref rid="CIT0019" ref-type="bibr">19</xref>,<xref rid="CIT0020" ref-type="bibr">20</xref>]. It is now possible to understand causes of emergence of antibiotic-resistant strains and to identify potential drug targets through combinatorial approaches involving comparative genomics, metabolomics, phylogenomics, evolutionary and structural biology/bioinformatics (<xref rid="F0001" ref-type="fig">Figure 1</xref>). Here we discuss the current status of drug discovery research in each area, focusing on the scope and applicability of computational approaches.
<fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>From mycobacterial genomes to drug discovery. Post-genomic application areas in mycobacterial drug discovery such as comparative genomics and structural biology/bioinformatics are shown.</p></caption><alternatives><graphic specific-use="web-only" content-type="color" xlink:href="TEMI_A_1561158_F0001_OC"/><graphic specific-use="print-only" content-type="black-white" xlink:href="TEMI_A_1561158_F0001_PB"/></alternatives></fig></p></sec></sec><sec id="S002"><title>Availability of genome sequences and annotation data: applications of comparative genomic approaches to drug discovery research</title><p>Comprehensive understanding of the organization of mycobacterial genomes began in 1998 with the elucidation of the complete genome sequence of <italic>M. tuberculosis</italic> [<xref rid="CIT0021" ref-type="bibr">21</xref>,<xref rid="CIT0022" ref-type="bibr">22</xref>]. The <italic>M. tuberculosis</italic> reference genome (H37Rv strain) is 4.41 Mbp in length and comprises 4081 protein genes, 13 pseudogenes, 45 tRNA genes, 30 ncRNA, 3 rRNA genes and 2 miscRNA genes (<ext-link ext-link-type="uri" xlink:href="http://svitsrv8.epfl.ch/tuberculist/">http://svitsrv8.epfl.ch/tuberculist/</ext-link>).</p><p>The genome of <italic>M. leprae</italic> was first sequenced in 2001 [<xref rid="CIT0023" ref-type="bibr">23</xref>]. This 3.2 Mbp genome has significant sequence similarity with that of <italic>M. tuberculosis</italic>; however, <italic>M. leprae</italic> reductively evolved to survive with 1614 protein genes, 1310 pseudogenes, 45 tRNA genes, 3 rRNA genes and 2 stable RNA genes (<ext-link ext-link-type="uri" xlink:href="http://svitsrv8.epfl.ch/mycobrowser/leprosy.html">http://svitsrv8.epfl.ch/mycobrowser/leprosy.html</ext-link>).</p><p>The complete genome of <italic>M. abscessus</italic> strain ATCC 19977 was first sequenced in 2008 [<xref rid="CIT0024" ref-type="bibr">24</xref>]. The 5.06 Mbp genome consists of 4941 genes encoding 2886 proteins with functional assignments and 2055 hypothetical proteins (<ext-link ext-link-type="uri" xlink:href="https://www.patricbrc.org/view/Genome/36809.5">https://www.patricbrc.org/view/Genome/36809.5</ext-link>).</p><p>Rapid annotation of genomic data, leading to the development of general purpose as well as specialized resources, described in Supplementary Table 1, is providing important information pertinent to sequence, structure, function, metabolic pathway, taxonomy and drug resistance mutations.</p><sec id="S002-S2001"><title>Comparative genomics: understanding strain diversity and emergence of drug-resistant strains</title><p>Most pathogenic mycobacterium species including <italic>M. tuberculosis</italic> and <italic>M. leprae</italic> are slow growers taking &#x0003e;7 days to form visible colonies on solid media. Comparative pan-genomic analyses indicate that the evolution of rapid and slow growers is attributed to a series of gene gain and gene loss events leading to adaptation to different environments [<xref rid="CIT0025" ref-type="bibr">25</xref>]. Classical methods for genotyping of mycobacterial strains include IS6110DNA fingerprinting, spoligotyping and 24 locus-MIRU (mycobacterial-interspersed repetitive units)-VNTR (variable number of tandem repeats) typing [<xref rid="CIT0026" ref-type="bibr">26</xref>]. With the availability of genome sequencing data, complete genome-based phylogenies are being used for genotyping and classification of mycobacteria [<xref rid="CIT0027" ref-type="bibr">27</xref>,<xref rid="CIT0028" ref-type="bibr">28</xref>]. The classical <italic>M. tuberculosis</italic> complex is subdivided into seven distinct lineages with characteristic geographic distribution [<xref rid="CIT0029" ref-type="bibr">29</xref>]. Genomic analyses revealed three subspecies of <italic>M. abscessus</italic>, namely <italic>M</italic>. <italic>abscessus</italic>, <italic>M. massiliense</italic> and <italic>M. bolleti</italic> [<xref rid="CIT0030" ref-type="bibr">30</xref>]. Likewise, lineage diversity within distinct subtypes of <italic>M. leprae</italic> has been recently studied based on phylogenomic analyses of 154 genomes [<xref rid="CIT0031" ref-type="bibr">31</xref>].</p><p>Molecular phylogenetics and evolutionary dynamics methods allow study of epidemiology and links between genetic diversity and emergence of drug resistance in mycobacterial strains [<xref rid="CIT0032" ref-type="bibr">32</xref>]. Antibiotic-resistant genes are important markers for delineation of evolution and spread of drug resistance [<xref rid="CIT0010" ref-type="bibr">10</xref>,<xref rid="CIT0014" ref-type="bibr">14</xref>,<xref rid="CIT0033" ref-type="bibr">33</xref>]. Such computational studies have helped to answer specific questions such as: Whether a particular phylogenetic lineage is associated with drug resistance in an outbreak/epidemic? When and how the drug-resistant strains have emerged? What are the evolutionary factors that cause antimicrobial drug resistance in mycobacterium? Computational studies on mycobacterium addressing each of these questions are described below.</p><p>Recently, genomic studies focusing on population structure, origin and spread of MDR-TB have been undertaken across various parts of the world [<xref rid="CIT0029" ref-type="bibr">29</xref>,<xref rid="CIT0034" ref-type="bibr">34&#x02013;36</xref>]. A study [<xref rid="CIT0034" ref-type="bibr">34</xref>] on strain diversity and phylogeography using genomes of 340 <italic>M. tuberculosis</italic> strains (isolated during 2008&#x02013;2013) from KwaZulu-Natal, helped to elucidate the timing of acquisitions of drug resistance mutations that confer XDR-TB, indicating that isoniazid-resistance evolved earlier than rifampicin-resistance<sup>.</sup> Similarly, molecular epidemiology of MDR-TB in Ireland has been systematically examined using genomes of <italic>M. tuberculosis</italic> strains isolated during 2001&#x02013;2014 from MDR-TB cases [<xref rid="CIT0035" ref-type="bibr">35</xref>]. Among seven lineages of MTB complex, Beijing lineage was observed to be associated with MDR [<xref rid="CIT0035" ref-type="bibr">35</xref>]. MDR-TB in Ireland was found to be introduced from other localities, as known for several European countries [<xref rid="CIT0037" ref-type="bibr">37</xref>].</p><p>In the case of <italic>M. abscessus</italic>, phylogenomic studies revealed the major role of recombination in causing lineage diversity [<xref rid="CIT0030" ref-type="bibr">30</xref>,<xref rid="CIT0038" ref-type="bibr">38</xref>,<xref rid="CIT0039" ref-type="bibr">39</xref>]. Population structure and recombination analyses provided significant evidence of gene flow and admixture among three lineages (<italic>M. abscessus</italic>, <italic>M. massiliense</italic>, and <italic>M. bolleti</italic>), and a correlation with pathogenicity and macrolide resistance in cystic fibrosis patients was found [<xref rid="CIT0039" ref-type="bibr">39</xref>]. Phylogenomic and genetic polymorphism analyses have also been carried out using <italic>M. abscessus</italic> isolates from US [<xref rid="CIT0040" ref-type="bibr">40</xref>]. A population genomic study [<xref rid="CIT0041" ref-type="bibr">41</xref>], based on the worldwide collection of clinical isolates of <italic>M. abscessus,</italic> has shown that the majority of <italic>M. abscessus</italic> infections are acquired through transmission (potentially via aerosols and fomites) of recently emerged circulating clones that have spread across the world. These clones are observed to be associated with increased virulence and worse clinical outcomes. This is a wake-up alarm! We are facing a pressing international infection challenge [<xref rid="CIT0041" ref-type="bibr">41</xref>].</p><p>In the case of <italic>M. leprae</italic>, a comprehensive study on phylogenomics and antibiotic resistance has been recently published [<xref rid="CIT0031" ref-type="bibr">31</xref>], which focuses on sequence and selection pressure analysis of wildtype as well as antibiotic-resistant genes. Several attempts have also been made to analyse the origin and spread of leprosy across various parts of the world [<xref rid="CIT0042" ref-type="bibr">42</xref>].</p><p>Thus, comparative genomics and phylogeographic studies are important in understanding the global spread and transmission dynamics of the mycobacterial infections. Strain diversity is shown to be one of the contributing factors to antibiotic resistance, linking transmission dynamics to medicine, across various geographic areas which are endemic for diseases such as TB [<xref rid="CIT0043" ref-type="bibr">43</xref>]. Furthermore, all these developments point to an increasing need for new and effective drugs to combat antibiotic resistance. Ideally, new drugs must have a novel mode of action to reduce events of cross-resistance, optimal dose-response, pharmacokinetic and toxicity profiles allowing safe and short duration of therapy either solely or in combination with other drugs. Comparative genomics of metabolic pathways provide a means to rapidly identify potential gene targets and thus could aid in drug discovery research (detailed in next section).</p></sec><sec id="S002-S2002"><title>Comparative pathway analyses and identification of essential genes</title><p><italic>M. tuberculosis</italic>, <italic>M. abscessus</italic> and <italic>M. leprae</italic> survive in distinct ecological niches with distinct evolving features that enable them to adapt to their specific environments. Malhotra et al. [<xref rid="CIT0044" ref-type="bibr">44</xref>] describe a 90% overlap of known and proposed drug targets against all mycobacterial species. The study identified the major pathways such as chorismate, purine/pyrimidine and amino acid biosynthetic pathways, essential for the survival of mycobacteria, as conserved in all these three species with minor differences in the carbon metabolism pathways.</p><p><italic>M. tuberculosis</italic> is known for its peculiar ability to survive in the human macrophage despite varying stress conditions (redox, acidic, and nitrosamine) within the host. This has contributed to a very elaborate DNA repair and recombination system. The most up-to-date metabolic reconstruction for <italic>M. tuberculosis</italic> describes 1228 metabolic reactions, 1011 genes and 998 metabolites [<xref rid="CIT0045" ref-type="bibr">45</xref>], where 250 protein-coding genes present in the lipid biosynthetic pathways are responsible for the thick cell wall. Mutations in these pathways give rise to further changes in their metabolic pathways.</p><p>Draft metabolic reconstruction for <italic>M. abscessus</italic> exists in BioCyc [<xref rid="CIT0046" ref-type="bibr">46</xref>] and KEGG [<xref rid="CIT0047" ref-type="bibr">47</xref>] databases, with 110 pathways including biosynthesis, metabolism, biodegradation and information processing pathways. Evolutionary analyses showed that <italic>M. abscessus</italic> is more closely related to other NTMs such as <italic>M. avium</italic> complex and has a well-supported membrane transport system with a large number of efflux pumps, resulting in multidrug-resistant features [<xref rid="CIT0048" ref-type="bibr">48</xref>]. As an opportunistic bacterium, <italic>M. abscessus</italic> is able to survive outside its host and also contains metabolic pathways not associated with pathogenesis, which contribute to its larger genome size as compared to obligate pathogens.</p><p>In case of <italic>M. leprae</italic>, reductive evolution has led to the loss of common catabolic pathways such as lipolysis and impairment of the energy metabolism pathways [<xref rid="CIT0023" ref-type="bibr">23</xref>]. Moreover, the production of cognate and prosthetic groups from transport, biosynthetic and electron transfer pathways is also affected [<xref rid="CIT0049" ref-type="bibr">49</xref>]. With the loss of several functions, and the presence of a large number of conserved but unknown functions of pseudogenes, further studies to characterize the metabolic pathways in <italic>M. leprae</italic> are required.</p></sec><sec id="S002-S2003"><title>Approaches to identify essential genes and prioritization of drug targets</title><p>The availability of genome sequences of mycobacteria, and annotations in sequence, structure and pathway databases facilitate systems-level analysis wherein comparative genomics and evolutionary bioinformatics approaches can be integrated to identify the minimal set of essential genes, leading to faster identification of putative drug targets. Essential genes that are necessary for the survival of the bacterium, and are critical components of metabolic and physico-chemical pathways, can be identified by gene knockouts, saturation transposon mutagenesis, RNA interference, etc. Essential genes have been characterized experimentally in the case of <italic>M. tuberculosis</italic> [<xref rid="CIT0050" ref-type="bibr">50&#x02013;52</xref>]. However, limited studies have been carried out in <italic>M. abscessus</italic> and <italic>M. leprae</italic>. Specifically, <italic>M. leprae</italic> cannot be cultured <italic>in vitro</italic> and thus demands computational identification of essential genes.</p><p>Computational approaches for identification of essential genes, including machine learning, flux balance analyses and comparative genomics [<xref rid="CIT0053" ref-type="bibr">53</xref>], are faster and cheaper than experimental methods [<xref rid="CIT0053" ref-type="bibr">53</xref>]. Machine learning methods utilize unique genomic features of essential genes such as length of proteins, codon usage, GC content, sub-cellular localization, higher rate of evolutionary conservation, etc. Dedicated resources such as Database of Essential Genes [<xref rid="CIT0054" ref-type="bibr">54</xref>] and the database of Online Gene Essentiality [<xref rid="CIT0055" ref-type="bibr">55</xref>] have been developed, which serve as a platform for identification and prioritization of essential drug targets in various species including <italic>M. leprae</italic> [<xref rid="CIT0056" ref-type="bibr">56</xref>]. Advent of next-generation sequencing has enabled design of comparative genomics workflows to identify essential genes in case of <italic>M. tuberculosis</italic> [<xref rid="CIT0057" ref-type="bibr">57</xref>].</p><p>Upon identification of a set of essential genes, prioritization of drug targets can be achieved by further screening of essential genes based on computational predictions of ADMET (absorption, distribution, metabolism, excretion and toxicity) properties, sub-cellular localization, etc. In view of growing concern about drug resistance, attempts have been made to prioritize drug targets based on various analyses such as identification of uniqueness in metabolome and similarities to known druggable proteins, analysis of the protein-protein interactome, flux balance analysis of reactome and sequence-structural analysis of targetability of genes using integrative strategies [<xref rid="CIT0058" ref-type="bibr">58</xref>,<xref rid="CIT0059" ref-type="bibr">59</xref>]. As most critical targets in a pathogenic organism are expected to be evolutionarily conserved, this has been applied to filter essential genes in <italic>M. tuberculosis</italic> [<xref rid="CIT0058" ref-type="bibr">58</xref>]. Likewise, convergent positive selection analyses were used to identify genes that possibly cause drug resistance in <italic>M. tuberculosis</italic> [<xref rid="CIT0059" ref-type="bibr">59</xref>]. Evolutionary rate has been proposed as a useful parameter for ranking and prioritizing antibacterial drug targets [<xref rid="CIT0060" ref-type="bibr">60</xref>]. Thus, understanding evolution of drug targets is one of the important aspects of the drug discovery, especially to tackle the problem of drug resistance.</p></sec></sec><sec id="S003"><title>Structural biology and bioinformatics to combat mycobacterial infections</title><p>Early approaches to the discovery of new antibiotics relied almost entirely on whole-cell phenotypic screening of natural products, microbial extracts and fermentation broths. This approach has helped in the discovery of most antibiotics in use to date and recently led to the approval of two new drugs, bedaquiline and delamanid, for the treatment of drug-resistant strains of TB [<xref rid="CIT0061" ref-type="bibr">61</xref>]. Structure-guided drug discovery, pioneered in academia and some companies in the 1970s became central to the discovery of antihypertensives that targeted renin and AIDS antivirals that targeted HIV protease in the 1980s and 1990s [<xref rid="CIT0062" ref-type="bibr">62&#x02013;64</xref>]. Opportunities for structure-guided drug discovery of mycobacterial targets became real only later when genome sequences became available. Understanding the structure and mechanism of the target allowed progress and optimization of hit-to-lead molecules, as well as a better understanding of resistance mechanisms, identifying causes of potential side effects and drug-drug interactions. This understanding led many research groups to perform high-throughput screening (HTS) and fragment-based screening campaigns of chemical libraries [<xref rid="CIT0065" ref-type="bibr">65</xref>] directly against carefully selected targets of interest. The applications of structure-guided drug discovery to mycobacteria have been reviewed earlier [<xref rid="CIT0066" ref-type="bibr">66&#x02013;68</xref>].</p><p>Structural features can also be used to further refine target selection and validation including lack of structural homology to human host to avoid mechanism-based toxicity and ligandability leading to modulation of target activity. Where the target protein has not been structurally or functionally characterized, it&#x02019;s structural model can be built based on homologous proteins using programs like MODELLER [<xref rid="CIT0069" ref-type="bibr">69</xref>]. Important information regarding target protein function and properties can be obtained from databases such as TubercuList (<ext-link ext-link-type="uri" xlink:href="http://svitsrv8.epfl.ch/tuberculist/">http://svitsrv8.epfl.ch/tuberculist/</ext-link>) or CHOPIN [<xref rid="CIT0070" ref-type="bibr">70</xref>]. Further, druggability of targets can be predicted by analysing properties and depths of various pockets/hotspots (capable of small-molecule binding interactions), using several databases and programs [<xref rid="CIT0071" ref-type="bibr">71</xref>].</p><sec id="S003-S2001"><title>Fragment-based drug discovery (FBDD): a promising alternative to HTS approach</title><p>The principal advantage of the FBDD approach compared to HTS methods is that very small libraries (&#x0003c;10<sup>3</sup> fragments) of low molecular weight (&#x0003c;300&#x02005;Da) compounds can be used to obtain good starting points for lead discovery [<xref rid="CIT0065" ref-type="bibr">65</xref>]. Initial fragment hits usually exhibit lower potency than the more complex molecules found in typical HTS compound libraries, but can be chemically optimized into lead candidates, thereby more effectively exploring the chemical space available for binding to the target protein [<xref rid="CIT0068" ref-type="bibr">68</xref>]. <xref rid="F0002" ref-type="fig">Figure 2</xref> illustrates a typical fragment screening cascade employed in our lab. The details of these steps are summarized in Supplementary File 1.
<fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>FBDD cascade. Various techniques involved in each of the four stages are shown.</p></caption><alternatives><graphic specific-use="web-only" content-type="color" xlink:href="TEMI_A_1561158_F0002_OC"/><graphic specific-use="print-only" content-type="black-white" xlink:href="TEMI_A_1561158_F0002_PB"/></alternatives></fig></p><p>FBDD approaches have been successfully applied to design inhibitors targeting various key <italic>M. tuberculosis</italic> enzymes such as pantothenate synthetase [<xref rid="CIT0072" ref-type="bibr">72</xref>], transcriptional repressor [<xref rid="CIT0073" ref-type="bibr">73</xref>], cytochrome P450 [<xref rid="CIT0074" ref-type="bibr">74</xref>], thymidylate kinase [<xref rid="CIT0075" ref-type="bibr">75</xref>] and malate synthase [<xref rid="CIT0076" ref-type="bibr">76</xref>]. Some of the lead molecules developed from such fragment-based campaigns showed promising inhibitory response against <italic>M. tuberculosis</italic>, as shown in the example in Supplementary Figure 1.</p></sec><sec id="S003-S2002"><title>Virtual screening, hotspot mapping and pharmacophore modelling to aid structure-guided drug discovery</title><p><italic>In-silico</italic> screening and docking of compound libraries often help to reduce the time and cost involved in experimental testing of large sets of compounds to identify potential hits. The effectiveness of such virtual screening exercises can be improved by complementing the analysis with fragment hotspot-mapping programs [<xref rid="CIT0071" ref-type="bibr">71</xref>], which identify regions within the protein that provide relatively large contribution towards ligand binding in addition to information on interactions governing the predicted regions. Several studies [<xref rid="CIT0077" ref-type="bibr">77</xref>,<xref rid="CIT0078" ref-type="bibr">78</xref>] have used an energy-based pharmacophore modelling approach to complement virtual screening, followed by chemical optimization to identify inhibitors. We have collaborated with Maria Paola Costi at the University of Modena in a similar study involving a combination of virtual screening and molecular dynamics simulation methods to identify novel chemical scaffolds targeting <italic>M. tuberculosis</italic> thymidylate synthase X [<xref rid="CIT0079" ref-type="bibr">79</xref>].</p><p>Phenotypic screening along with advances in chemical genetics and bioinformatics has allowed target-guided compound identification and optimization [<xref rid="CIT0080" ref-type="bibr">80</xref>], by utilizing target mechanism-based whole-cell screening or by genetic manipulation of the target phenotype, or by finding targets directly from phenotypic hits [<xref rid="CIT0081" ref-type="bibr">81</xref>]. The latter approach can employ various techniques such as whole genome sequencing to identify resistant mutants [<xref rid="CIT0082" ref-type="bibr">82</xref>,<xref rid="CIT0083" ref-type="bibr">83</xref>], transcriptional profiling [<xref rid="CIT0084" ref-type="bibr">84</xref>], chemical biology and metabolomics [<xref rid="CIT0085" ref-type="bibr">85</xref>] or in-silico methods [<xref rid="CIT0086" ref-type="bibr">86</xref>]. These advances in the field discussed above, coupled with a comprehensive understanding of the chemical space of mycobacterial drugs, hold promise of accelerating the process of mycobacterial drug discovery.</p></sec><sec id="S003-S2003"><title>From genomes to proteomes: automated modelling of proteomes through structural genomics and bioinformatics</title><p>Methods to identify structures that are potentially similar to the protein in question (<italic>templates</italic>) have been developed in our laboratory [<xref rid="CIT0087" ref-type="bibr">87</xref>] and elsewhere (reviewed in [<xref rid="CIT0088" ref-type="bibr">88</xref>]), as well as methods such as MODELLER [<xref rid="CIT0069" ref-type="bibr">69</xref>] and Rosetta [<xref rid="CIT0089" ref-type="bibr">89</xref>] to leverage this similarity to build theoretical, comparative models based on target-template alignments. Community-wide efforts, such as Critical Assessment Structure Prediction [<xref rid="CIT0090" ref-type="bibr">90</xref>] have led to substantial improvements in the accuracy of these approaches, both in terms of template identification and alignment, as well as model building and refinement. However, most of these methods focus on producing a single, most likely structure of each protein.</p><p>Our group has developed a structural genomics resource for <italic>M. tuberculosis</italic> (H37Rv strain) called CHOPIN [<xref rid="CIT0070" ref-type="bibr">70</xref>] which provides an ensemble of predicted models in different conformational states. These models are generated through a homology modelling pipeline. Development of such structural resources is important to identify potential therapeutic targets [<xref rid="CIT0091" ref-type="bibr">91</xref>].</p></sec><sec id="S003-S2004"><title>Moving beyond proteomes: understanding the impact of drug-resistant mutations in drug targets</title><p>Mutations are likely to confer drug resistance by altering the energy landscape of the target protein, affecting the protein-protein interactions or affecting the drug/ligand binding with the target protein. Computational approaches to predict the effects of mutations on the structure and function of proteins can prove helpful in understanding the mechanism of drug resistance. Our lab has developed two well-established methods, SDM (Site Directed Mutator), based on a statistical approach using Environment Specific Substitution Tables [<xref rid="CIT0092" ref-type="bibr">92</xref>] and mCSM (mutation Cutoff Scanning Matrix), a machine learning approach [<xref rid="CIT0093" ref-type="bibr">93</xref>] to predict the structural and functional effects of mutations on the target proteins. mCSM is available in different flavours to predict the effects of mutations on protein stability (mCSM-stability), protein-protein interactions (mCSM-PPI) and protein-ligand interactions (mCSM-lig) [<xref rid="CIT0094" ref-type="bibr">94</xref>]. Additionally, in order to determine the impact of mutations on flexible protein conformations, tools like EnCOM [<xref rid="CIT0095" ref-type="bibr">95</xref>] and FoldX [<xref rid="CIT0096" ref-type="bibr">96</xref>] have been developed. Such methods have been used by our group and others to gain insights into the mechanism of mutations in various genetic and mycobacterial diseases including leprosy [<xref rid="CIT0097" ref-type="bibr">97&#x02013;100</xref>]. Such analyses of the structural and functional mechanism of drug resistance causing mutations using computational approaches are very helpful in the rapid assessment of many mutations not easily achieved using experimental methods.</p></sec></sec><sec id="S004"><title>Challenges and future perspectives</title><p>This review has focused on the importance of advances in sequence and structure determination of genomes and their protein products in efforts to develop structure-guided drug discovery against three mycobacteria: <italic>M. tuberculosis</italic>, <italic>M. abscessus</italic> and <italic>M. leprae</italic>. Although <italic>M. tuberculosis</italic> is the most studied mycobacterium, 3D structures of only &#x0223c;16% of gene products have been determined experimentally. Sequence-structure homology recognition and comparative modelling have proved useful in providing clues about druggability. Furthermore, the more accurate models, based on structures of close homologues, can provide a basis for virtual screening and ligand design.</p><p>Metabolic reconstructions are providing insights into how <italic>M</italic>. <italic>tuberculosis</italic> has adapted within the host, and similar studies in <italic>M. abscessus</italic> and <italic>M. leprae</italic> are needed to provide better understanding of pathogenesis and design of new treatment regimes. The current focus in many laboratories is on providing user-friendly databases for the structural proteomes, and extending these not only to structures of homo- and hetero-oligomers, and complexes with natural and synthetic ligands, but also to incorporate data on metabolic pathways and epistasis, which are important in target selection.</p><p>The target-guided approach for antibiotic drug development has generally led to a low rate of translation of <italic>in-vitro</italic> inhibitory response to bactericidal/bacteriostatic activity. This challenge requires further study not only of physico-chemical properties of compounds affecting permeability of the thick waxy cell envelopes of mycobacteria, but also of drug efflux pumps and metabolic inactivation of compounds by bacterial/host cell enzymes that affect compound bioavailability. The emergence of drug resistance through mutations in the target is also a growing challenge. We have developed systematic mutagenesis studies using our software with a view to identify regions where drug design might be directed with a minimal chance of resistance. This is likely to be a key component in drug discovery in future, especially through structure-guided fragment-based approaches, where choices of fragment elaboration or cross-linking can be made in the light of such analyses of mutability.</p></sec></body><back><sec id="S005"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the authors.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shinnick</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Good</surname><given-names>R.</given-names></name></person-group><article-title>Mycobacterial taxonomy</article-title>. <source>Eur J Clin Microbiol Infect Dis</source>. <year>1994</year>;<volume>13</volume>:<fpage>884</fpage>&#x02013;<lpage>901</lpage>.<pub-id pub-id-type="pmid">7698114</pub-id></mixed-citation></ref><ref id="CIT0002"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forbes</surname><given-names>BA.</given-names></name></person-group><article-title>Mycobacterial taxonomy</article-title>. <source>J Clin Microbiol</source>. <year>2017</year>;<volume>55</volume>:<fpage>380</fpage>.<pub-id pub-id-type="pmid">27927928</pub-id></mixed-citation></ref><ref id="CIT0003"><label>[3]</label><mixed-citation publication-type="standard"><person-group person-group-type="author"><collab>WHO</collab></person-group>
<comment>Global tuberculosis report 2017</comment>; <year>2017</year>.</mixed-citation></ref><ref id="CIT0004"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prevots</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Loddenkemper</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Sotgiu</surname><given-names>G</given-names></name>, <etal>et al.</etal></person-group><article-title>Nontuberculous mycobacterial pulmonary disease: an increasing burden with substantial costs</article-title>. <source>Eur Respir J</source>. <year>2017</year>;<volume>49</volume>:<fpage>1700374</fpage>.<pub-id pub-id-type="pmid">28446563</pub-id></mixed-citation></ref><ref id="CIT0005"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stout</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Koh</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Yew</surname><given-names>WW.</given-names></name></person-group><article-title>Update on pulmonary disease due to non-tuberculous mycobacteria</article-title>. <source>Int J Infect Dis</source>. <year>2016</year>;<volume>45</volume>:<fpage>123</fpage>&#x02013;<lpage>134</lpage>.<pub-id pub-id-type="pmid">26976549</pub-id></mixed-citation></ref><ref id="CIT0006"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Efthimiou</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hodson</surname><given-names>ME</given-names></name>, <etal>et al.</etal></person-group><article-title>Mycobacterial isolations in young adults with cystic fibrosis</article-title>. <source>Thorax</source>. <year>1984</year>;<volume>39</volume>:<fpage>369</fpage>&#x02013;<lpage>375</lpage>.<pub-id pub-id-type="pmid">6429879</pub-id></mixed-citation></ref><ref id="CIT0007"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodman</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Polis</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Heltshe</surname><given-names>SL</given-names></name>, <etal>et al.</etal></person-group><article-title>Late diagnosis defines a unique population of long-term survivors of cystic fibrosis</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2005</year>;<volume>171</volume>:<fpage>621</fpage>&#x02013;<lpage>626</lpage>.<pub-id pub-id-type="pmid">15591474</pub-id></mixed-citation></ref><ref id="CIT0008"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silver</surname><given-names>LL.</given-names></name></person-group><article-title>Challenges of antibacterial discovery</article-title>. <source>Clin Microbiol Rev</source>. <year>2011</year>;<volume>24</volume>:<fpage>71</fpage>&#x02013;<lpage>109</lpage>.<pub-id pub-id-type="pmid">21233508</pub-id></mixed-citation></ref><ref id="CIT0009"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#x02019;Ambrosio</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Centis</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Sotgiu</surname><given-names>G</given-names></name>, <etal>et al.</etal></person-group><article-title>New anti-tuberculosis drugs and regimens: 2015 update</article-title>. <source>ERJ Open Res</source>. <year>2015</year>;<volume>1</volume>:<fpage>00010-2015</fpage>.<pub-id pub-id-type="pmid">27730131</pub-id></mixed-citation></ref><ref id="CIT0010"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gygli</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Borrell</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Trauner</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group><article-title>Antimicrobial resistance in <italic>Mycobacterium tuberculosis</italic>: mechanistic and evolutionary perspectives</article-title>. <source>FEMS Microbiol Rev</source>. <year>2017</year>;<volume>41</volume>:<fpage>354</fpage>&#x02013;<lpage>373</lpage>.<pub-id pub-id-type="pmid">28369307</pub-id></mixed-citation></ref><ref id="CIT0011"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dookie</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Rambaran</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Padayatchi</surname><given-names>N</given-names></name>, <etal>et al.</etal></person-group><article-title>Evolution of drug resistance in <italic>Mycobacterium tuberculosis</italic>: a review on the molecular determinants of resistance and implications for personalized care</article-title>. <source>J Antimicrob Chemother</source>. <year>2018</year>;<volume>73</volume>:<fpage>1138</fpage>&#x02013;<lpage>1151</lpage>.<pub-id pub-id-type="pmid">29360989</pub-id></mixed-citation></ref><ref id="CIT0012"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nessar</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Cambau</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Reyrat</surname><given-names>JM</given-names></name>, <etal>et al.</etal></person-group><article-title><italic>Mycobacterium abscessus</italic>: a new antibiotic nightmare</article-title>. <source>J Antimicrob Chemother</source>. <year>2012</year>;<volume>67</volume>:<fpage>810</fpage>&#x02013;<lpage>818</lpage>.<pub-id pub-id-type="pmid">22290346</pub-id></mixed-citation></ref><ref id="CIT0013"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saunderson</surname><given-names>PR.</given-names></name></person-group><article-title>Drug-resistant <italic>M leprae</italic></article-title>. <source>Clin Dermatol</source>. <year>2016</year>;<volume>34</volume>:<fpage>79</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">26773627</pub-id></mixed-citation></ref><ref id="CIT0014"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Davies</surname><given-names>D.</given-names></name></person-group><article-title>Origins and evolution of antibiotic resistance</article-title>. <source>Microbiol Mol Biol Rev</source>. <year>2010</year>;<volume>74</volume>:<fpage>417</fpage>&#x02013;<lpage>433</lpage>.<pub-id pub-id-type="pmid">20805405</pub-id></mixed-citation></ref><ref id="CIT0015"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Variava</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Martinson</surname><given-names>N.</given-names></name></person-group><article-title>Drug-resistant tuberculosis: the rise of the monos</article-title>. <source>Lancet Infect Dis</source>. <year>2018</year>;<volume>18</volume>:<fpage>705</fpage>&#x02013;<lpage>706</lpage>.<pub-id pub-id-type="pmid">29685457</pub-id></mixed-citation></ref><ref id="CIT0016"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lange</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Chesov</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Heyckendorf</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group><article-title>Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment</article-title>. <source>Respirology</source>. <year>2018</year>;<volume>23</volume>:<fpage>656</fpage>&#x02013;<lpage>673</lpage>.<pub-id pub-id-type="pmid">29641838</pub-id></mixed-citation></ref><ref id="CIT0017"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Chu</surname><given-names>H</given-names></name>, <etal>et al.</etal></person-group><article-title>Rapid detection of mutations in <italic>erm</italic>(41) and <italic>rrl</italic> associated with clarithromycin resistance in <italic>Mycobacterium abscessus</italic> complex by denaturing gradient gel electrophoresis</article-title>. <source>J Microbiol Methods</source>. <year>2017</year>;<volume>143</volume>:<fpage>87</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="pmid">29079298</pub-id></mixed-citation></ref><ref id="CIT0018"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bell</surname><given-names>G</given-names></name>, <name name-style="western"><surname>MacLean</surname><given-names>C.</given-names></name></person-group><article-title>The search for &#x02018;evolution-proof&#x02019; antibiotics</article-title>. <source>Trends Microbiol</source>. <year>2017</year>;<volume>26</volume>:<fpage>471</fpage>&#x02013;<lpage>483</lpage>.<pub-id pub-id-type="pmid">29191398</pub-id></mixed-citation></ref><ref id="CIT0019"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pucci</surname><given-names>MJ.</given-names></name></person-group><article-title>Use of genomics to select antibacterial targets</article-title>. <source>Biochem Pharmacol</source>. <year>2006</year>;<volume>71</volume>:<fpage>1066</fpage>&#x02013;<lpage>1072</lpage>.<pub-id pub-id-type="pmid">16412986</pub-id></mixed-citation></ref><ref id="CIT0020"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mills</surname><given-names>SD.</given-names></name></person-group><article-title>When will the genomics investment pay off for antibacterial discovery?</article-title><source>Biochem Pharmacol</source>. <year>2006</year>;<volume>71</volume>:<fpage>1096</fpage>&#x02013;<lpage>1102</lpage>.<pub-id pub-id-type="pmid">16387281</pub-id></mixed-citation></ref><ref id="CIT0021"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cole</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Brosch</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Parkhill</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group><article-title>Deciphering the biology of <italic>Mycobacterium tuberculosis</italic> from the complete genome sequence</article-title>. <source>Nature</source>. <year>1998</year>;<volume>393</volume>:<fpage>537</fpage>.<pub-id pub-id-type="pmid">9634230</pub-id></mixed-citation></ref><ref id="CIT0022"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brosch</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Gordon</surname><given-names>SV</given-names></name>, <name name-style="western"><surname>Billault</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group><article-title>Use of a <italic>Mycobacterium tuberculosis</italic> H37Rv bacterial artificial chromosome library for genome mapping, sequencing, and comparative genomics</article-title>. <source>Infect Immun</source>. <year>1998</year>;<volume>66</volume>:<fpage>2221</fpage>&#x02013;<lpage>2229</lpage>.<pub-id pub-id-type="pmid">9573111</pub-id></mixed-citation></ref><ref id="CIT0023"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cole</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Eiglmeier</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Parkhill</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group><article-title>Massive gene decay in the leprosy bacillus</article-title>. <source>Nature</source>. <year>2001</year>;<volume>409</volume>:<fpage>1007</fpage>.<pub-id pub-id-type="pmid">11234002</pub-id></mixed-citation></ref><ref id="CIT0024"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ripoll</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Pasek</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Schenowitz</surname><given-names>C</given-names></name>, <etal>et al.</etal></person-group><article-title>Non mycobacterial virulence genes in the genome of the emerging pathogen <italic>Mycobacterium abscessus</italic></article-title>. <source>PloS One</source>. <year>2009</year>;<volume>4</volume>:<fpage>e5660</fpage>.<pub-id pub-id-type="pmid">19543527</pub-id></mixed-citation></ref><ref id="CIT0025"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wee</surname><given-names>WY</given-names></name>, <name name-style="western"><surname>Dutta</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Choo</surname><given-names>SW.</given-names></name></person-group><article-title>Comparative genome analyses of mycobacteria give better insights into their evolution</article-title>. <source>PloS One</source>. <year>2017</year>;<volume>12</volume>:<fpage>e0172831</fpage>.<pub-id pub-id-type="pmid">28291784</pub-id></mixed-citation></ref><ref id="CIT0026"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sch&#x000fc;rch</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>van Soolingen</surname><given-names>D.</given-names></name></person-group><article-title>Dna fingerprinting of <italic>Mycobacterium tuberculosis</italic>: from phage typing to whole-genome sequencing</article-title>. <source>Infect Genet Evol</source>. <year>2012</year>;<volume>12</volume>:<fpage>602</fpage>&#x02013;<lpage>609</lpage>.<pub-id pub-id-type="pmid">22067515</pub-id></mixed-citation></ref><ref id="CIT0027"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roetzer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Diel</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Kohl</surname><given-names>TA</given-names></name>, <etal>et al.</etal></person-group><article-title>Whole genome sequencing versus traditional genotyping for investigation of a <italic>Mycobacterium tuberculosis</italic> outbreak: a longitudinal molecular epidemiological study</article-title>. <source>PLoS Med</source>. <year>2013</year>;<volume>10</volume>:<fpage>e1001387</fpage>.<pub-id pub-id-type="pmid">23424287</pub-id></mixed-citation></ref><ref id="CIT0028"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walker</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Ip</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Harrell</surname><given-names>RH</given-names></name>, <etal>et al.</etal></person-group><article-title>Whole-genome sequencing to delineate <italic>Mycobacterium tuberculosis</italic> outbreaks: a retrospective observational study</article-title>. <source>Lancet Infect Dis</source>. <year>2013</year>;<volume>13</volume>:<fpage>137</fpage>&#x02013;<lpage>146</lpage>.<pub-id pub-id-type="pmid">23158499</pub-id></mixed-citation></ref><ref id="CIT0029"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niemann</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Supply</surname><given-names>P.</given-names></name></person-group><article-title>Diversity and evolution of <italic>Mycobacterium tuberculosis</italic>: moving to whole-genome-based approaches</article-title>. <source>Cold Spring Harb Perspect Med</source>. <year>2014</year>;<volume>4</volume>:<fpage>a021188</fpage>.<pub-id pub-id-type="pmid">25190252</pub-id></mixed-citation></ref><ref id="CIT0030"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sassi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Drancourt</surname><given-names>M.</given-names></name></person-group><article-title>Genome analysis reveals three genomospecies in <italic>Mycobacterium abscessus</italic></article-title>. <source>BMC Genomics</source>. <year>2014</year>;<volume>15</volume>:<fpage>359</fpage>.<pub-id pub-id-type="pmid">24886480</pub-id></mixed-citation></ref><ref id="CIT0031"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benjak</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Avanzi</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>P</given-names></name>, <etal>et al.</etal></person-group><article-title>Phylogenomics and antimicrobial resistance of the leprosy bacillus <italic>Mycobacterium leprae</italic></article-title>. <source>Nat Commun</source>. <year>2018</year>;<volume>9</volume>:<fpage>352</fpage>.<pub-id pub-id-type="pmid">29367657</pub-id></mixed-citation></ref><ref id="CIT0032"><label>[32]</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Borrell</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Trauner</surname><given-names>A.</given-names></name></person-group><source>Strain variation in the <italic>Mycobacterium tuberculosis</italic> complex: its role in biology, epidemiology and control</source>. In: <comment>Gagneux S, editor. Advances in experimental medicine and biology, Vol. 1019, Chapter 14. Cham: Springer</comment>; <year>2017</year>
<comment>p. 263&#x02013;279</comment>.</mixed-citation></ref><ref id="CIT0033"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aminov</surname><given-names>RI</given-names></name>, <name name-style="western"><surname>Mackie</surname><given-names>RI.</given-names></name></person-group><article-title>Evolution and ecology of antibiotic resistance genes</article-title>. <source>FEMS Microbiol Lett</source>. <year>2007</year>;<volume>271</volume>:<fpage>147</fpage>&#x02013;<lpage>161</lpage>.<pub-id pub-id-type="pmid">17490428</pub-id></mixed-citation></ref><ref id="CIT0034"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Abeel</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Manson McGuire</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group><article-title>Evolution of extensively drug-resistant tuberculosis over four decades: whole genome sequencing and dating analysis of <italic>Mycobacterium tuberculosis</italic> isolates from KwaZulu-Natal</article-title>. <source>PLoS Med</source>. <year>2015</year>;<volume>12</volume>:<fpage>e1001880</fpage>.<pub-id pub-id-type="pmid">26418737</pub-id></mixed-citation></ref><ref id="CIT0035"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roycroft</surname><given-names>E</given-names></name>, <name name-style="western"><surname>O&#x02019;Toole</surname><given-names>RF</given-names></name>, <name name-style="western"><surname>Fitzgibbon</surname><given-names>MM</given-names></name>, <etal>et al.</etal></person-group><article-title>Molecular epidemiology of multi-and extensively-drug-resistant <italic>Mycobacterium tuberculosis</italic> in Ireland, 2001&#x02013;2014</article-title>. <source>J Infect</source>. <year>2018</year>;<volume>76</volume>:<fpage>55</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">29031637</pub-id></mixed-citation></ref><ref id="CIT0036"><label>[36]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merker</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kohl</surname><given-names>TA</given-names></name>, <name name-style="western"><surname>Roetzer</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group><article-title>Whole genome sequencing reveals complex evolution patterns of multidrug-resistant <italic>Mycobacterium tuberculosis</italic> Beijing strains in patients</article-title>. <source>PloS One</source>. <year>2013</year>;<volume>8</volume>:<fpage>e82551</fpage>.<pub-id pub-id-type="pmid">24324807</pub-id></mixed-citation></ref><ref id="CIT0037"><label>[37]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Beer</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kodmon</surname><given-names>C</given-names></name>, <name name-style="western"><surname>van der Werf</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group><article-title>Molecular surveillance of multi-and extensively drug-resistant tuberculosis transmission in the European Union from 2003 to 2011</article-title>. <source>Euro Surveill</source>. <year>2014</year>;<volume>19</volume>:<fpage>pii: 20742</fpage>.</mixed-citation></ref><ref id="CIT0038"><label>[38]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Ng</surname><given-names>KP</given-names></name>, <name name-style="western"><surname>Ong</surname><given-names>CS</given-names></name>, <etal>et al.</etal></person-group><article-title>Genomic comparisons reveal microevolutionary differences in <italic>Mycobacterium abscessus</italic> subspecies</article-title>. <source>Front Microbiol</source>. <year>2017</year>;<volume>8</volume>:<fpage>2042</fpage>.<pub-id pub-id-type="pmid">29109707</pub-id></mixed-citation></ref><ref id="CIT0039"><label>[39]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sapriel</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Konjek</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Orgeur</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group><article-title>Genome-wide mosaicism within <italic>Mycobacterium abscessus</italic>: evolutionary and epidemiological implications</article-title>. <source>BMC Genomics</source>. <year>2016</year>;<volume>17</volume>:<fpage>118</fpage>.<pub-id pub-id-type="pmid">26884275</pub-id></mixed-citation></ref><ref id="CIT0040"><label>[40]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davidson</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Hasan</surname><given-names>NA</given-names></name>, <name name-style="western"><surname>Reynolds</surname><given-names>PR</given-names></name>, <etal>et al.</etal></person-group><article-title>Genome sequencing of <italic>Mycobacterium abscessus</italic> isolates from patients in the United States and comparisons to globally diverse clinical strains</article-title>. <source>J Clin Microbiol</source>. <year>2014</year>;<volume>52</volume>:<fpage>3573</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">25056330</pub-id></mixed-citation></ref><ref id="CIT0041"><label>[41]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bryant</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Grogono</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Rodriguez-Rincon</surname><given-names>D</given-names></name>, <etal>et al.</etal></person-group><article-title>Population-level genomics identifies the emergence and global spread of a human transmissible multidrug-resistant nontuberculous mycobacterium</article-title>. <source>Science</source>. <year>2016</year>;<volume>354</volume>:<fpage>751</fpage>&#x02013;<lpage>757</lpage>.<pub-id pub-id-type="pmid">27846606</pub-id></mixed-citation></ref><ref id="CIT0042"><label>[42]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monot</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Honor&#x000e9;</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Garnier</surname><given-names>T</given-names></name>, <etal>et al.</etal></person-group><article-title>Comparative genomic and phylogeographic analysis of <italic>Mycobacterium leprae</italic></article-title>. <source>Nat Genet</source>. <year>2009</year>;<volume>41</volume>:<fpage>1282</fpage>.<pub-id pub-id-type="pmid">19881526</pub-id></mixed-citation></ref><ref id="CIT0043"><label>[43]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perdig&#x000e3;o</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Clemente</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ramos</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group><article-title>Genetic diversity, transmission dynamics and drug resistance of <italic>Mycobacterium tuberculosis</italic> in Angola</article-title>. <source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>:<fpage>42814</fpage>.<pub-id pub-id-type="pmid">28230095</pub-id></mixed-citation></ref><ref id="CIT0044"><label>[44]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malhotra</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Vedithi</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Blundell</surname><given-names>TL.</given-names></name></person-group><article-title>Decoding the similarities and differences among Mycobacterial species</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2017</year>;<volume>11</volume>:<fpage>e0005883</fpage>.<pub-id pub-id-type="pmid">28854187</pub-id></mixed-citation></ref><ref id="CIT0045"><label>[45]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kavvas</surname><given-names>ES</given-names></name>, <name name-style="western"><surname>Seif</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yurkovich</surname><given-names>JT</given-names></name>, <etal>et al.</etal></person-group><article-title>Updated and standardized genome-scale reconstruction of <italic>Mycobacterium tuberculosis</italic> H37Rv, iEK1011, simulates flux states indicative of physiological conditions</article-title>. <source>BMC Syst Biol</source>. <year>2018</year>;<volume>12</volume>:<fpage>25</fpage>.<pub-id pub-id-type="pmid">29499714</pub-id></mixed-citation></ref><ref id="CIT0046"><label>[46]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caspi</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Billington</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ferrer</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group><article-title>The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases</article-title>. <source>Nucleic Acids Res</source>. <year>2016</year>;<volume>44</volume>:<fpage>D471</fpage>&#x02013;<lpage>D480</lpage>.<pub-id pub-id-type="pmid">26527732</pub-id></mixed-citation></ref><ref id="CIT0047"><label>[47]</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Kanehisa</surname><given-names>M.</given-names></name></person-group><source>&#x02018;In silico&#x02019; simulation of biological processes: Novartis foundation symposium 247</source>.<publisher-name>Wiley Online Library</publisher-name>; <year>2002</year> p. <fpage>91</fpage>&#x02013;<lpage>103</lpage>.</mixed-citation></ref><ref id="CIT0048"><label>[48]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shanmugham</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>A.</given-names></name></person-group><article-title>Identification and characterization of potential therapeutic candidates in emerging human pathogen <italic>Mycobacterium abscessus</italic>: a novel hierarchical in silico approach</article-title>. <source>PloS One</source>. <year>2013</year>;<volume>8</volume>:<fpage>e59126</fpage>.<pub-id pub-id-type="pmid">23527108</pub-id></mixed-citation></ref><ref id="CIT0049"><label>[49]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Cole</surname><given-names>ST.</given-names></name></person-group><article-title><italic>Mycobacterium leprae</italic>: genes, pseudogenes and genetic diversity</article-title>. <source>Future Microbiol</source>. <year>2011</year>;<volume>6</volume>:<fpage>57</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">21162636</pub-id></mixed-citation></ref><ref id="CIT0050"><label>[50]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Griffin</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Gawronski</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>DeJesus</surname><given-names>MA</given-names></name>, <etal>et al.</etal></person-group><article-title>High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism</article-title>. <source>PLoS Pathog</source>. <year>2011</year>;<volume>7</volume>:<fpage>e1002251</fpage>.<pub-id pub-id-type="pmid">21980284</pub-id></mixed-citation></ref><ref id="CIT0051"><label>[51]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sassetti</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Boyd</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Rubin</surname><given-names>EJ.</given-names></name></person-group><article-title>Genes required for mycobacterial growth defined by high density mutagenesis</article-title>. <source>Mol Microbiol</source>. <year>2003</year>;<volume>48</volume>:<fpage>77</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">12657046</pub-id></mixed-citation></ref><ref id="CIT0052"><label>[52]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeJesus</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Gerrick</surname><given-names>ER</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>W</given-names></name>, <etal>et al.</etal></person-group><article-title>Comprehensive essentiality analysis of the <italic>Mycobacterium tuberculosis</italic> genome via saturating transposon mutagenesis</article-title>. <source>MBio</source>. <year>2017</year>;<volume>8</volume>:<fpage>e02133-16</fpage>.<pub-id pub-id-type="pmid">28096490</pub-id></mixed-citation></ref><ref id="CIT0053"><label>[53]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>H</given-names></name>, <etal>et al.</etal></person-group><article-title>A comprehensive overview of online resources to identify and predict bacterial essential genes</article-title>. <source>Front Microbiol</source>. <year>2017</year>;<volume>8</volume>:<fpage>2331</fpage>.<pub-id pub-id-type="pmid">29230204</pub-id></mixed-citation></ref><ref id="CIT0054"><label>[54]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ou</surname><given-names>HY</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>CT.</given-names></name></person-group><article-title>Deg: a database of essential genes</article-title>. <source>Nucleic Acids Res</source>. <year>2004</year>;<volume>32</volume>:<fpage>271D</fpage>&#x02013;<lpage>D272</lpage>.<pub-id pub-id-type="pmid">14715925</pub-id></mixed-citation></ref><ref id="CIT0055"><label>[55]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W-H</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>X</given-names></name>, <etal>et al.</etal></person-group><article-title>Ogee v2: an update of the online gene essentiality database with special focus on differentially essential genes in human cancer cell lines</article-title>. <source>Nucleic Acids Res</source>. <year>2017</year>;<volume>45</volume>(<issue>D1</issue>):<fpage>D940</fpage>&#x02013;<lpage>D944</lpage>.<pub-id pub-id-type="pmid">27799467</pub-id></mixed-citation></ref><ref id="CIT0056"><label>[56]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uddin</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Azam</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Wadood</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group><article-title>Computational identification of potential drug targets against <italic>Mycobacterium leprae</italic></article-title>. <source>Med Chem Res</source>. <year>2016</year>;<volume>25</volume>:<fpage>473</fpage>&#x02013;<lpage>481</lpage>.</mixed-citation></ref><ref id="CIT0057"><label>[57]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghosh</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Baloni</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Mukherjee</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group><article-title>A multi-level multi-scale approach to study essential genes in <italic>Mycobacterium tuberculosis</italic></article-title>. <source>BMC Syst Biol</source>. <year>2013</year>;<volume>7</volume>:<fpage>132</fpage>.<pub-id pub-id-type="pmid">24308365</pub-id></mixed-citation></ref><ref id="CIT0058"><label>[58]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaur</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kutum</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Dash</surname><given-names>D</given-names></name>, <etal>et al.</etal></person-group><article-title>Data intensive genome level analysis for identifying novel, non-toxic drug targets for multi drug resistant <italic>Mycobacterium tuberculosis</italic></article-title>. <source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>:<fpage>46595</fpage>.<pub-id pub-id-type="pmid">28425478</pub-id></mixed-citation></ref><ref id="CIT0059"><label>[59]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farhat</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Shapiro</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Kieser</surname><given-names>KJ</given-names></name>, <etal>et al.</etal></person-group><article-title>Genomic analysis identifies targets of convergent positive selection in drug-resistant <italic>Mycobacterium tuberculosis</italic></article-title>. <source>Nat Genet</source>. <year>2013</year>;<volume>45</volume>:<fpage>1183</fpage>.<pub-id pub-id-type="pmid">23995135</pub-id></mixed-citation></ref><ref id="CIT0060"><label>[60]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gladki</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kaczanowski</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Szczesny</surname><given-names>P</given-names></name>, <etal>et al.</etal></person-group><article-title>The evolutionary rate of antibacterial drug targets</article-title>. <source>BMC Bioinformatics</source>. <year>2013</year>;<volume>14</volume>:<fpage>36</fpage>.<pub-id pub-id-type="pmid">23374913</pub-id></mixed-citation></ref><ref id="CIT0061"><label>[61]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguta</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Appiah-Opong</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Nyarko</surname><given-names>AK</given-names></name>, <etal>et al.</etal></person-group><article-title>Current perspectives in drug discovery against tuberculosis from natural products</article-title>. <source>Int J Mycobacteriol</source>. <year>2015</year>;<volume>4</volume>:<fpage>165</fpage>&#x02013;<lpage>183</lpage>.<pub-id pub-id-type="pmid">27649863</pub-id></mixed-citation></ref><ref id="CIT0062"><label>[62]</label><mixed-citation publication-type="standard"><person-group person-group-type="author"><name name-style="western"><surname>Sibanda</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Pearl</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Hemmings</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group><comment>Acta crystallographica section A C42-C42. Copenhagen: Munksgaard</comment>.</mixed-citation></ref><ref id="CIT0063"><label>[63]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blundell</surname><given-names>TL.</given-names></name></person-group><article-title>Structure-based drug design</article-title>. <source>Nature</source>. <year>1996</year>;<volume>384</volume>:<fpage>23</fpage>&#x02013;<lpage>26</lpage>.</mixed-citation></ref><ref id="CIT0064"><label>[64]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blundell</surname><given-names>TL.</given-names></name></person-group><article-title>Protein crystallography and drug discovery: recollections of knowledge exchange between academia and industry</article-title>. <source>IUCrJ</source>. <year>2017</year>;<volume>4</volume>:<fpage>308</fpage>&#x02013;<lpage>321</lpage>.</mixed-citation></ref><ref id="CIT0065"><label>[65]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blundell</surname><given-names>TL</given-names></name>, <name name-style="western"><surname>Jhoti</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Abell</surname><given-names>C.</given-names></name></person-group><article-title>High-throughput crystallography for lead discovery in drug design</article-title>. <source>Nat Rev Drug Discov</source>. <year>2002</year>;<volume>1</volume>:<fpage>45</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">12119609</pub-id></mixed-citation></ref><ref id="CIT0066"><label>[66]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendes</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Blundell</surname><given-names>TL.</given-names></name></person-group><article-title>Targeting tuberculosis using structure-guided fragment-based drug design</article-title>. <source>Drug Discov Today</source>. <year>2017</year>;<volume>22</volume>:<fpage>546</fpage>&#x02013;<lpage>554</lpage>.<pub-id pub-id-type="pmid">27742535</pub-id></mixed-citation></ref><ref id="CIT0067"><label>[67]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malhotra</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Montano</surname><given-names>BO</given-names></name>, <etal>et al.</etal></person-group><article-title>Structure-guided, target-based drug discovery&#x02013;exploiting genome information from HIV to mycobacterial infections</article-title>. <source>Postepy Biochem</source>. <year>2016</year>;<volume>62</volume>:<fpage>262</fpage>&#x02013;<lpage>272</lpage>.<pub-id pub-id-type="pmid">28132480</pub-id></mixed-citation></ref><ref id="CIT0068"><label>[68]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Mendes</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>SY</given-names></name>, <etal>et al.</etal></person-group><article-title>Structural biology and the design of new therapeutics: from HIV and cancer to mycobacterial infections: a paper dedicated to John Kendrew</article-title>. <source>J Mol Biol</source>. <year>2017</year>;<volume>429</volume>:<fpage>2677</fpage>&#x02013;<lpage>2693</lpage>.<pub-id pub-id-type="pmid">28648615</pub-id></mixed-citation></ref><ref id="CIT0069"><label>[69]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#x00160;ali</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Blundell</surname><given-names>TL.</given-names></name></person-group><article-title>Comparative protein modelling by satisfaction of spatial restraints</article-title>. <source>J Mol Biol</source>. <year>1993</year>;<volume>234</volume>:<fpage>779</fpage>&#x02013;<lpage>815</lpage>.<pub-id pub-id-type="pmid">8254673</pub-id></mixed-citation></ref><ref id="CIT0070"><label>[70]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ochoa-Monta&#x000f1;o</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Mohan</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Blundell</surname><given-names>TL.</given-names></name></person-group><article-title>Chopin: a web resource for the structural and functional proteome of <italic>Mycobacterium tuberculosis</italic></article-title>. <source>Database</source>. <year>2015</year>;<comment>2015</comment>
<comment>pii:bav026</comment>.</mixed-citation></ref><ref id="CIT0071"><label>[71]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radoux</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Olsson</surname><given-names>TS</given-names></name>, <name name-style="western"><surname>Pitt</surname><given-names>WR</given-names></name>, <etal>et al.</etal></person-group><article-title>Identifying interactions that determine fragment binding at protein hotspots</article-title>. <source>J Med Chem</source>. <year>2016</year>;<volume>59</volume>:<fpage>4314</fpage>&#x02013;<lpage>4325</lpage>.<pub-id pub-id-type="pmid">27043011</pub-id></mixed-citation></ref><ref id="CIT0072"><label>[72]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hung</surname><given-names>AW</given-names></name>, <name name-style="western"><surname>Silvestre</surname><given-names>HL</given-names></name>, <name name-style="western"><surname>Wen</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group><article-title>Optimization of inhibitors of <italic>Mycobacterium tuberculosis</italic> pantothenate synthetase based on group efficiency analysis</article-title>. <source>Chem Med Chem</source>. <year>2016</year>;<volume>11</volume>:<fpage>38</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">26486566</pub-id></mixed-citation></ref><ref id="CIT0073"><label>[73]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nikiforov</surname><given-names>PO</given-names></name>, <name name-style="western"><surname>Blaszczyk</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Surade</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group><article-title>Fragment-sized EthR inhibitors exhibit exceptionally strong ethionamide boosting effect in whole-cell <italic>Mycobacterium tuberculosis</italic> assays</article-title>. <source>ACS Chem Biol</source>. <year>2017</year>;<volume>12</volume>:<fpage>1390</fpage>&#x02013;<lpage>1396</lpage>.<pub-id pub-id-type="pmid">28314097</pub-id></mixed-citation></ref><ref id="CIT0074"><label>[74]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kavanagh</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Coyne</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>McLean</surname><given-names>KJ</given-names></name>, <etal>et al.</etal></person-group><article-title>Fragment-based approaches to the development of <italic>Mycobacterium tuberculosis</italic> CYP121 inhibitors</article-title>. <source>J Med Chem</source>. <year>2016</year>;<volume>59</volume>:<fpage>3272</fpage>&#x02013;<lpage>3302</lpage>.<pub-id pub-id-type="pmid">27002486</pub-id></mixed-citation></ref><ref id="CIT0075"><label>[75]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naik</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Raichurkar</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bandodkar</surname><given-names>BS</given-names></name>, <etal>et al.</etal></person-group><article-title>Structure guided lead generation for <italic>M. tuberculosis</italic> thymidylate kinase (Mtb TMK): discovery of 3-cyanopyridone and 1, 6-naphthyridin-2-one as potent inhibitors</article-title>. <source>J Med Chem</source>. <year>2015</year>;<volume>58</volume>:<fpage>753</fpage>&#x02013;<lpage>766</lpage>.<pub-id pub-id-type="pmid">25486447</pub-id></mixed-citation></ref><ref id="CIT0076"><label>[76]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>H-L</given-names></name>, <name name-style="western"><surname>Krieger</surname><given-names>IV</given-names></name>, <name name-style="western"><surname>Parai</surname><given-names>MK</given-names></name>, <etal>et al.</etal></person-group><article-title><italic>Mycobacterium tuberculosis</italic> malate synthase structures with fragments reveal a portal for substrate/product exchange</article-title>. <source>J Biol Chem</source>. <year>2016</year>;<volume>M116</volume>:<fpage>750877</fpage>.</mixed-citation></ref><ref id="CIT0077"><label>[77]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poyraz</surname><given-names>OM</given-names></name>, <name name-style="western"><surname>Jeankumar</surname><given-names>VU</given-names></name>, <name name-style="western"><surname>Saxena</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group><article-title>Structure-guided design of novel thiazolidine inhibitors of O-acetyl serine sulfhydrylase from <italic>Mycobacterium tuberculosis</italic></article-title>. <source>J Med Chem</source>. <year>2013</year>;<volume>56</volume>:<fpage>6457</fpage>&#x02013;<lpage>6466</lpage>.<pub-id pub-id-type="pmid">23879381</pub-id></mixed-citation></ref><ref id="CIT0078"><label>[78]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devi</surname><given-names>PB</given-names></name>, <name name-style="western"><surname>Samala</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Sridevi</surname><given-names>JP</given-names></name>, <etal>et al.</etal></person-group><article-title>Structure-guided design of thiazolidine derivatives as <italic>Mycobacterium tuberculosis</italic> pantothenate synthetase inhibitors</article-title>. <source>Chem Med Chem</source>. <year>2014</year>;<volume>9</volume>:<fpage>2538</fpage>&#x02013;<lpage>2547</lpage>.<pub-id pub-id-type="pmid">25155986</pub-id></mixed-citation></ref><ref id="CIT0079"><label>[79]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luciani</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Saxena</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Surade</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group><article-title>Virtual screening and X-ray crystallography identify non-substrate analog inhibitors of flavin-dependent thymidylate synthase</article-title>. <source>J Med Chem</source>. <year>2016</year>;<volume>59</volume>:<fpage>9269</fpage>&#x02013;<lpage>9275</lpage>.<pub-id pub-id-type="pmid">27589670</pub-id></mixed-citation></ref><ref id="CIT0080"><label>[80]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zuniga</surname><given-names>ES</given-names></name>, <name name-style="western"><surname>Early</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Parish</surname><given-names>T.</given-names></name></person-group><article-title>The future for early-stage tuberculosis drug discovery</article-title>. <source>Future Microbiol</source>. <year>2015</year>;<volume>10</volume>:<fpage>217</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">25689534</pub-id></mixed-citation></ref><ref id="CIT0081"><label>[81]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abrahams</surname><given-names>GL</given-names></name>, <name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Savvi</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group><article-title>Pathway-selective sensitization of <italic>Mycobacterium tuberculosis</italic> for target-based whole-cell screening</article-title>. <source>Chem Biol</source> . <year>2012</year>;<volume>19</volume>:<fpage>844</fpage>&#x02013;<lpage>854</lpage>.<pub-id pub-id-type="pmid">22840772</pub-id></mixed-citation></ref><ref id="CIT0082"><label>[82]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aggarwal</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Parai</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Shetty</surname><given-names>N</given-names></name>, <etal>et al.</etal></person-group><article-title>Development of a novel lead that targets <italic>M. tuberculosis</italic> polyketide synthase 13</article-title>. <source>Cell</source>. <year>2017</year>;<volume>170</volume>:<fpage>249</fpage>&#x02013;<lpage>259.e25</lpage>.<pub-id pub-id-type="pmid">28669536</pub-id></mixed-citation></ref><ref id="CIT0083"><label>[83]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Donini</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Pacitto</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group><article-title>The inosine monophosphate dehydrogenase, GuaB2, is a vulnerable new bactericidal drug target for tuberculosis</article-title>. <source>ACS Infect Dis</source>. <year>2017</year>;<volume>3</volume>:<fpage>5</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">27726334</pub-id></mixed-citation></ref><ref id="CIT0084"><label>[84]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boshoff</surname><given-names>HI</given-names></name>, <name name-style="western"><surname>Myers</surname><given-names>TG</given-names></name>, <name name-style="western"><surname>Copp</surname><given-names>BR</given-names></name>, <etal>et al.</etal></person-group><article-title>The transcriptional responses of <italic>Mycobacterium tuberculosis</italic> to inhibitors of metabolism novel insights into drug mechanisms of action</article-title>. <source>J Biol Chem</source>. <year>2004</year>;<volume>279</volume>:<fpage>40174</fpage>&#x02013;<lpage>40184</lpage>.<pub-id pub-id-type="pmid">15247240</pub-id></mixed-citation></ref><ref id="CIT0085"><label>[85]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prosser</surname><given-names>GA</given-names></name>, <name name-style="western"><surname>de Carvalho</surname><given-names>LP.</given-names></name></person-group><article-title>Metabolomics reveal d-alanine: d-alanine ligase as the target of d-cycloserine in <italic>Mycobacterium tuberculosis</italic></article-title>. <source>ACS Med Chem Lett</source>. <year>2013</year>;<volume>4</volume>:<fpage>1233</fpage>&#x02013;<lpage>1237</lpage>.<pub-id pub-id-type="pmid">24478820</pub-id></mixed-citation></ref><ref id="CIT0086"><label>[86]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mugumbate</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Mendes</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Blaszczyk</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group><article-title>Target identification of <italic>mycobacterium tuberculosis</italic> phenotypic hits using a concerted chemogenomic, biophysical, and structural approach</article-title>. <source>Front Pharmacol</source>. <year>2017</year>;<volume>8</volume>:<fpage>681</fpage>.<pub-id pub-id-type="pmid">29018348</pub-id></mixed-citation></ref><ref id="CIT0087"><label>[87]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Blundell</surname><given-names>TL</given-names></name>, <name name-style="western"><surname>Mizuguchi</surname><given-names>K.</given-names></name></person-group><article-title>Fugue: sequence-structure homology recognition using environment-specific substitution tables and structure-dependent gap penalties</article-title>. <source>J Mol Biol</source>. <year>2001</year>;<volume>310</volume>:<fpage>243</fpage>&#x02013;<lpage>257</lpage>.<pub-id pub-id-type="pmid">11419950</pub-id></mixed-citation></ref><ref id="CIT0088"><label>[88]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorn</surname><given-names>M</given-names></name>, <name name-style="western"><surname>e Silva</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Buriol</surname><given-names>LS</given-names></name>, <etal>et al.</etal></person-group><article-title>Three-dimensional protein structure prediction: methods and computational strategies</article-title>. <source>Comput Biol Chem</source>. <year>2014</year>;<volume>53</volume>:<fpage>251</fpage>&#x02013;<lpage>276</lpage>.</mixed-citation></ref><ref id="CIT0089"><label>[89]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>DiMaio</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>RY-R</given-names></name>, <etal>et al.</etal></person-group><article-title>High-resolution comparative modeling with RosettaCM</article-title>. <source>Structure</source>. <year>2013</year>;<volume>21</volume>:<fpage>1735</fpage>&#x02013;<lpage>1742</lpage>.<pub-id pub-id-type="pmid">24035711</pub-id></mixed-citation></ref><ref id="CIT0090"><label>[90]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moult</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Fidelis</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kryshtafovych</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group><article-title>Critical assessment of methods of protein structure prediction (CASP)&#x02014;round XII</article-title>. <source>Proteins: Struct, Funct, Bioinf</source>. <year>2018</year>;<volume>86</volume>:<fpage>7</fpage>&#x02013;<lpage>15</lpage>.</mixed-citation></ref><ref id="CIT0091"><label>[91]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassan</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Tiwari</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Guimar&#x000e3;es</surname><given-names>LC</given-names></name>, <etal>et al.</etal></person-group><article-title>Proteome scale comparative modeling for conserved drug and vaccine targets identification in <italic>Corynebacterium pseudotuberculosis</italic></article-title>. <source>BMC Genomics</source>. <year>2014</year>;<volume>15</volume>(<issue>S3</issue>).</mixed-citation></ref><ref id="CIT0092"><label>[92]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Worth</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Preissner</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Blundell</surname><given-names>TL.</given-names></name></person-group><article-title>Sdm&#x02014;a server for predicting effects of mutations on protein stability and malfunction</article-title>. <source>Nucleic Acids Res</source>. <year>2011</year>;<volume>39</volume>:<fpage>W215</fpage>&#x02013;<lpage>W222</lpage>.<pub-id pub-id-type="pmid">21593128</pub-id></mixed-citation></ref><ref id="CIT0093"><label>[93]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pires</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Ascher</surname><given-names>DB</given-names></name>, <name name-style="western"><surname>Blundell</surname><given-names>TL.</given-names></name></person-group><article-title>Mcsm: predicting the effects of mutations in proteins using graph-based signatures</article-title>. <source>Bioinformatics</source>. <year>2014</year>;<volume>30</volume>:<fpage>335</fpage>&#x02013;<lpage>342</lpage>.<pub-id pub-id-type="pmid">24281696</pub-id></mixed-citation></ref><ref id="CIT0094"><label>[94]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pires</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Blundell</surname><given-names>TL</given-names></name>, <name name-style="western"><surname>Ascher</surname><given-names>DB.</given-names></name></person-group><article-title>mCSM-lig: quantifying the effects of mutations on protein-small molecule affinity in genetic disease and emergence of drug resistance</article-title>. <source>Sci Rep</source>. <year>2016</year>;<volume>6</volume>:<fpage>29575</fpage>.<pub-id pub-id-type="pmid">27384129</pub-id></mixed-citation></ref><ref id="CIT0095"><label>[95]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frappier</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Chartier</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Najmanovich</surname><given-names>RJ.</given-names></name></person-group><article-title>Encom server: exploring protein conformational space and the effect of mutations on protein function and stability</article-title>. <source>Nucleic Acids Res</source>. <year>2015</year>;<volume>43</volume>:<fpage>W395</fpage>&#x02013;<lpage>W400</lpage>.<pub-id pub-id-type="pmid">25883149</pub-id></mixed-citation></ref><ref id="CIT0096"><label>[96]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schymkowitz</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Borg</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Stricher</surname><given-names>F</given-names></name>, <etal>et al.</etal></person-group><article-title>The FoldX web server: an online force field</article-title>. <source>Nucleic Acids Res</source>. <year>2005</year>;<volume>33</volume>:<fpage>W382</fpage>&#x02013;<lpage>W388</lpage>.<pub-id pub-id-type="pmid">15980494</pub-id></mixed-citation></ref><ref id="CIT0097"><label>[97]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vedithi</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Malhotra</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Das</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group><article-title>Structural implications of mutations conferring rifampin resistance in <italic>mycobacterium leprae</italic></article-title>. <source>Sci Rep</source>. <year>2018</year>;<volume>8</volume>:<fpage>5016</fpage>.<pub-id pub-id-type="pmid">29567948</pub-id></mixed-citation></ref><ref id="CIT0098"><label>[98]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pires</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Blundell</surname><given-names>TL</given-names></name>, <etal>et al.</etal></person-group><article-title>In silico functional dissection of saturation mutagenesis: Interpreting the relationship between phenotypes and changes in protein stability, interactions and activity</article-title>. <source>Sci Rep</source>. <year>2016</year>;<volume>6</volume>:<fpage>19848</fpage>.<pub-id pub-id-type="pmid">26797105</pub-id></mixed-citation></ref><ref id="CIT0099"><label>[99]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forman</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Worth</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Bickerton</surname><given-names>GRJ</given-names></name>, <etal>et al.</etal></person-group><article-title>Structural bioinformatics mutation analysis reveals genotype&#x02013;phenotype correlations in von Hippel-Lindau disease and suggests molecular mechanisms of tumorigenesis</article-title>. <source>Proteins: Struct, Funct, Bioinf</source>. <year>2009</year>;<volume>77</volume>:<fpage>84</fpage>&#x02013;<lpage>96</lpage>.</mixed-citation></ref><ref id="CIT0100"><label>[100]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pandurangan</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Ascher</surname><given-names>DB</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>SE</given-names></name>, <etal>et al.</etal></person-group><article-title>Genomes, structural biology and drug discovery: combating the impacts of mutations in genetic disease and antibiotic resistance</article-title>. <source>Biochem Soc Trans</source>. <year>2017</year>;<volume>45</volume>:<fpage>303</fpage>&#x02013;<lpage>311</lpage>.<pub-id pub-id-type="pmid">28408471</pub-id></mixed-citation></ref></ref-list></back></article>